Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •1. Introduction
- •2. The Initial Phase of Drug Delivery Systems
- •3. Recent Drug Delivery Systems
- •4. Drug Delivery via Carriers
- •5.4 Polymer-Lipid Hybrid Nanoparticles Drug Delivery System
- •5.5 Self-Micro Emulsifying Drug Delivery System
- •5.6 In Situ Gel Drug Delivery System
- •5.8 Targeted Drug Delivery
- •6. Ceramic-Based Drug Delivery System
- •7. Polysaccharide-Based Drug Delivery System
- •8. Closed Loop Insulin Delivery System
- •9. Liposome-Mediated Drug Delivery
- •5. Recent Drug Delivery Systems
- •5.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •10. Dendrimers
- •11. PEGylated Drug Delivery System
- •12. Antibody-Drug Conjugate System
- •13. Mesoporous Silica-Based Drug Delivery
- •14. Transdermal Drug Delivery System
- •15. Hydrogel-Mediated Ocular Drug Delivery
- •16. Challenges with Current Drug Delivery Systems
- •17. Future Direction and Conclusion
- •References
- •1. Introduction
- •2. Pharmacokinetic Principles
- •2.1 Application of the Pharmacokinetic Principle in the Biomedical Fields
- •3. Cell Membrane/Biological Membrane
- •3.1 Passage of Drugs Across Biological Membranes
- •3.1.1 Simple Transport
- •3.1.2 Specialized Transport
- •4. Routes of Drug Administration
- •4.1 Oral (Enteral) Versus Parenteral Administration
- •4.2 Various Routes of Drug Administration
- •5. Absorption
- •5.1 Factors Affecting Absorption of Drugs
- •5.1.1 Physio-chemical Characteristics
- •5.1.2 Dosage Form
- •5.1.3 Concentration and Volume
- •5.1.4 Blood Flow
- •5.1.5 Surface Area
- •5.1.6 Administration Route
- •5.1.7 Disease States
- •5.2 Gastrointestinal Tract
- •5.3 Parenteral Sites
- •5.4 Pulmonary Sites (Alveoli)
- •5.5 Topical Sites
- •6. Distribution
- •6.1 Factors Affecting Distribution of Drugs
- •6.1.1 Physicochemical Properties of the Drug
- •6.1.2 Binding to Plasma and Tissue Proteins
- •6.1.3 Blood Flow and Organ Size
- •6.1.4 Specialized Compartments and Barriers
- •6.1.5 Specialized Transport Systems
- •6.1.6 Disease States
- •6.1.7 Physiological Factors
- •7. Metabolism/Biotransformation
- •7.1 Functions of Metabolism
- •7.2 Sites of Metabolism
- •7.3.1 Microsomal Enzymes
- •7.3.2 Non-microsomal Enzymes
- •7.4 Pathways of Biotransformation
- •8. Excretion
- •8.1 Routes of Excretion
- •8.1.1 Renal Excretion of Drugs
- •8.1.2 Extra-Renal Excretion of Drugs
- •9.1 Minimum Effective Concentration (MEC)
- •9.2 Maximum Safe Concentration (MSC) or Minimum Toxic Concentration (MTC)
- •9.4 Area Under the Curve (AUC)
- •9.5 Peak Effect
- •9.7 Onset of Action
- •9.8 Onset Time
- •9.9 Duration of Action
- •10. Order of Pharmacokinetic Processes
- •10.1 Zero-Order Kinetics
- •10.2 First-Order Kinetics
- •10.3 Mixed-Order Kinetics
- •11. Pharmacokinetic Models
- •11.1 Compartmental Models
- •11.3 Physiological Models
- •12. Determinants of Pharmacokinetics
- •12.1 Absorption
- •12.1.1 Bioavailability
- •12.1.2 Bioequivalence
- •12.1.3 Area Under Curve (AUC)
- •12.2 Distribution
- •12.2.1 Volume of Distribution
- •12.3 Elimination
- •12.3.2 Clearance (Cl) or Body Clearance
- •13. Conclusion
- •References
- •1. Introduction
- •2. Principles of Targeted Drug Delivery
- •3.1 Changes in pH and Salt Development
- •3.7 Dendrimers
- •4.1 Small-Sized Molecule-Based Targeting Strategies
- •4.2 Nucleic Acid Fragment-Based Targeting Strategies
- •4.3 Peptide- and Antibody-Based Targeting Strategies
- •4.4 Cell-Based Targeting Strategies
- •5. Conclusion
- •References
- •3.4 Liposomes
- •3.5 Solid Lipid Nanoparticles
- •3.6 Co-crystal Preparation
- •1. Introduction
- •2. History
- •3.1 Organic Nanoparticles
- •3.2 Inorganic Nanoparticles
- •4. Nanotechnology-Based Drug Delivery Systems
- •4.1 Smart Drug Delivery Systems
- •4.3 Multifunctional Drug Carriers
- •4.4 Organic/Inorganic Composites
- •5. Nanoparticulate Drug Delivery Systems
- •5.1 Liposomes
- •5.2 Microemulsions
- •5.3 Nanoparticles
- •6. Applications
- •6.1 Enhanced Drug Delivery
- •6.2 Overcoming Biological Barriers
- •6.3 Controlled Drug Release
- •6.4 Combination Therapy
- •6.5 Personalized Medicine
- •7. Limitations
- •7.1 Complexity and Cost
- •7.2 Biocompatibility and Toxicity
- •7.3 Stability and Shelf Life
- •7.4 Drug Loading and Release
- •7.5 Biological Barriers and Clearance
- •8. Conclusions
- •References
- •1. Introduction
- •2. Guidelines for Design of Lipid-Based Formulations
- •3. Formulation Strategies
- •3.1 Lipid Nanoparticles
- •3.1.1 Solid Lipid Nanoparticles (SLNs)
- •3.1.2 Nanostructured Lipid Carriers (NLCs)
- •3.2 Liposomes
- •3.2.1 Conventional Liposomes
- •3.2.2 PEGylated Liposomes
- •3.2.3 Multifunctional Liposomes
- •3.3 Microemulsions and Self-micro Emulsifying Drug Delivery Systems (SMEDDS)
- •3.4 Hybrid Systems
- •3.4.1 Lipid-Polymer Hybrid Nanoparticles
- •3.4.2 Lipid-Protein Hybrid Systems
- •4. Advanced Characterization Methods
- •4.1 In Vitro and In Vivo Assessment
- •4.1.1 Dissolution Studies
- •4.1.2 Permeability Studies
- •4.2 Imaging Techniques
- •4.2.1 Electron Microscopy
- •4.2.2 Fluorescence Imaging
- •Fluorescent Probes
- •Confocal Microscopy
- •4.2.3 Magnetic Resonance Imaging (MRI)
- •4.3 Stability Studies
- •4.3.1 Oxidative Stability
- •4.3.2 Thermal Stability
- •5. Applications of Lipid-Based Drug Delivery Systems
- •5.1 Cancer Therapy
- •5.1.1 Targeted Drug Delivery
- •5.1.2 Combination Therapy
- •5.2 Central Nervous System Disorders
- •5.2.2 Neuroprotective Effects
- •5.3 Antiviral and Antimicrobial Applications
- •5.3.1 Lipid Nanoparticles for Antiviral Drugs
- •5.3.2 Antibiotic Delivery Systems
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •3. Design and Characterization of Polymeric Drug Delivery Systems
- •4. Responsive Polymers
- •4.1 Polymeric Hydrogels
- •4.1.1 Characterization of Polymeric Hydrogels
- •Structural Analysis
- •Functional Analysis
- •4.2 Polymeric Micelles
- •4.2.1 Characterization of Polymeric Micelle
- •Critical Micelle Concentration Determination (CMC)
- •Morphological Characterization
- •Physicochemical Characterization
- •4.3 Liposomes
- •4.3.1 Ethosome
- •4.3.2 Transferosome
- •4.3.3 Niosome
- •4.4 Polyplexes or Polymer-Drug Conjugates
- •4.4.1 Dendrimers
- •4.4.2 Polymer-Protein Conjugates
- •4.4.3 Polymeric Nanoparticles
- •5. Conclusion
- •6. Future Prospects
- •References
- •1. Introduction
- •2.1 Types of Stimuli
- •3. Mechanism of Stimuli Responsiveness
- •3.1 pH-Responsive Systems
- •4. Materials
- •4.1 pH-Responsive Materials
- •4.4 Synthetic Thermo-Responsive Materials
- •4.7 Magnetic Responsive Materials
- •4.8.1 Intrinsically Conducting Polymers
- •4.8.2 Hydrogels
- •5. Methods
- •5.1 pH-Responsive Drug Delivery Systems
- •6. Conclusion
- •7. Notes
- •References
- •1. Introduction
- •3. Basic Features Required for the Biomaterial
- •4. Characteristics of Biomaterials
- •6. Biocompatibility as the Crucial Item
- •7. Biomaterials in Drug Delivery
- •8. Controlled Drug Delivery
- •9. Clinical Need for Controlled Drug Delivery
- •10. Biomaterials for Controlled Release of Small Molecules
- •11. Bioresponsive Polymers: From Design to Implementation
- •11.3 Hydrolysis and Enzymatically Responsive Polymers
- •11.7 Swelling and Contracting Polymers
- •12. Transdermal Drug Delivery Systems
- •12.1 Barriers to Transdermal Delivery
- •12.2 Development of Transdermal Drug Delivery Patches
- •12.3 Hydrogels Versus Non-hydrogel Polymeric Patches
- •12.4 Patches Based on Biopolymers
- •12.5 Patches Based on Synthetic Polymers
- •12.6 Drug Particles/Carriers
- •12.7 Commercial Patches
- •13. Smart Biomaterials
- •14. Conclusion and Future Perspective
- •References
- •1. Introduction
- •1.1 Historical Evolution
- •2. Skin Anatomy and Physiology
- •2.1 Cutaneous Layer Organization
- •2.2 Cutaneous Barrier Function
- •3. Mechanisms of Transdermal Drug Delivery
- •4. Formulation Strategies for Transdermal Drug Delivery
- •4.1 Drug Selection Criteria
- •4.2 Vehicle and Excipient Considerations
- •4.3 Permeation Enhancers
- •4.4 Transdermal Drug Delivery Technologies
- •5. Evaluation Methods for Transdermal Drug Delivery Systems
- •6. Applications of Transdermal Drug Delivery
- •6.1 Therapeutic Areas
- •6.2 Case Studies of Successful Transdermal Products
- •7. Regulatory Considerations and Approval Process
- •7.1 FDA Guidelines for Transdermal Drug Delivery Systems
- •7.2 Quality Control and Manufacturing Standards
- •7.3 Clinical Trial Requirements
- •8. Challenges and Future Perspectives
- •8.1 Overcoming Cutaneous Barrier Properties
- •8.2 Expanding the Range of Deliverable Drugs
- •8.3 Intelligent and Responsive Transdermal Systems
- •8.4 Integration with Other Drug Delivery Technologies
- •8.5 Conclusion
- •References
- •1. Background
- •2. Importance of the Tumor Microenvironment (TME) in Cancer Progression and Therapy
- •2.1 Components of the TME
- •2.2 Therapeutic Targeting of the TME
- •2.3 Impact of Standard Therapies on the TME
- •3. Tumor-Homing Peptides
- •3.1 Different Strategies for Targeting Peptides to Tumor Microenvironment
- •3.2 Applications and Development
- •3.3 Examples and Discoveries
- •4. Tumor Microenvironment Responsive Drug Delivery Systems (DDSS)
- •5. Nanoparticle-Based Smart Drug Delivery Systems
- •5.1.1 Endogenous Stimulus-Responsive Drug Delivery Systems (DDSs)
- •5.1.2 Exogenous Stimulus-Responsive DDSs
- •5.2.2 Dynamic Strategies for Tumor Targeting
- •6. Challenges and Opportunities for Targeted Delivery to Cancer Cells
- •7. Future Directions
- •8. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Types of Biosensors
- •2.1.2 Smart Polymers
- •2.1.3 Microfabricated Devices
- •2.2.1 Enzyme-Based Biosensors
- •2.2.2 Antibody-Based Biosensors
- •2.2.3 Aptamer-Based Biosensors
- •2.2.4 Whole-Cell-Based Biosensors
- •3. Methods
- •3.1 Approach Toward Designing Biosensors
- •3.1.1 Selection of the Analyte and Bioreceptors
- •3.1.2 Immobilization of Biosensors
- •3.1.3 Selection of Transducer
- •3.2 Green Biosensors
- •3.3 Challenges in Development of Biosensors-Based Drug Delivery Systems
- •References
- •1. Introduction
- •3. Ocular Barriers Hindering Absorption of Drugs
- •3.1 Precorneal Barriers
- •3.1.1 Tear Film, Tear Turnover, and Nasolacrimal Duct Drainage
- •3.1.3 Conjunctival and Scleral Barriers
- •3.2 Corneal Barrier
- •3.3 Blood-Ocular Barriers
- •4. Various Routes for Ocular Drug Delivery
- •4.1 Topical Administration
- •4.2 Subconjunctival Administration
- •4.3 Transscleral Administration
- •4.4 Intracameral Administration
- •4.5 Intravitreal Injections/Implants (IVIs)
- •4.6 Retrobulbar Administration
- •4.7 Systemic Administration
- •5. Nanotechnology-Based Ocular Drug Delivery Platforms
- •5.1 Nanoparticles (NPs)
- •5.1.1 Polymeric Nanoparticles (PNPs)
- •5.2 Nanomicelles
- •5.3 Nanoemulsions (NEs)
- •5.4 Nanosuspensions
- •5.5 Nanocrystals (NCs)
- •5.6 Liposomes
- •5.7 Microemulsions
- •5.8 Niosomes
- •5.10 Dendrimers
- •5.11 Nanowafers
- •5.12 Cubosomes
- •5.13 Bilosomes
- •5.14 Olaminosomes
- •5.15 Contact Lenses
- •5.16 Hydrogels
- •5.17 Microneedles (MNs)
- •6. Alternative Ocular Drug Delivery Approaches
- •6.1 Gene Therapy
- •6.1.1 Viral Vectors
- •6.1.2 Non-viral Vectors
- •6.1.3 Antisense Oligonucleotides (ASOs), RNAi, CRISPR-Cas9
- •6.2 Exosomes
- •6.3 Self-nano Emulsifying Drug Delivery Structures (SNEDDS)
- •7. Clinical Status of Nanotechnology-Based Ocular Drug Delivery Systems
- •8. Future Outlooks
- •References
- •1. Introduction
- •2. Anatomy and Physiology of GIT
- •2.1 Mouth and Esophagus
- •2.2 Stomach
- •2.3 Small Intestine
- •2.4 Ruminant Digestive System
- •3. Blood Supply
- •4. Nerve Supply
- •5. Challenges in GIT Drug Delivery
- •5.1 Acidic Environment of the Stomach
- •5.2 Alkaline pH of the Intestine
- •5.3 Variable GI Transit Times
- •6. Future Opportunities in GIT Drug Delivery
- •6.1.1 Targeted Delivery Systems
- •6.1.2 Ligand-Conjugated Nanoparticles
- •6.1.3 Liposomes
- •6.1.4 Solid Lipid Nanoparticles
- •6.2 Controlled Release Systems
- •6.2.1 Osmotic Pumps
- •6.2.2 Matrix Systems
- •6.3 Mucoadhesive Systems
- •6.3.1 Mucoadhesive Polymers
- •6.4 Absorption Enhancers
- •6.5 Tight Junction Modulators
- •6.6 Development of Prodrugs
- •7. Conclusion
- •References
- •1. Introduction
- •2. Anatomy and Physiology of the Respiratory System
- •3. Traditional Methods of Respiratory Drug Delivery
- •3.1 Metered-Dose Inhalers (MDIs)
- •3.2 Dry Powder Inhalers (DPIs)
- •3.3 Nebulizers
- •3.5 Improved Patient Compliance Through User-Friendly Devices
- •3.8 Enhanced Absorption by Overcoming Biological Barriers
- •3.9 Macromolecule Delivery Facilitation
- •3.10 Reduced Side Effects Through Improved Targeting
- •3.11 Formulation Challenges Addressed
- •3.12 Smart Technology Integration for Personalized Treatment
- •3.13 Environmental Sustainability Considerations
- •4. Novel Drug Delivery Approaches
- •4.2 Liposomal Formulations
- •5. Advanced Inhalation Devices
- •6. Targeted Drug Delivery Strategies
- •6.2 pH-Responsive Drug Release
- •7. Emerging Therapeutics for Respiratory Diseases
- •8.2 Combination Therapies
- •8.3 Prodrug Approaches
- •9. Personalized Medicine in Respiratory Drug Delivery
- •10. Future Perspectives and Emerging Technologies
- •10.1 3D-Printed Inhalers
- •11. Conclusion
- •References
- •1. Introduction
- •2. Delivery of Small Molecules
- •3. Drawbacks of Conventional Drug Delivery System
- •4. Factors Affecting Cardiovascular Drug Targeting System
- •4.1 Particle Shape
- •4.2 Particle Size
- •4.3 Particle Density
- •4.4 Flow Characteristics
- •5. Various Targeted Drug Delivery Systems
- •5.1 Application of Exosomes and EVs (Extracellular Vesicles)
- •5.4 Nanomedicines in Cardiovascular Therapy
- •5.5 PLGA-Based Nanoparticles
- •5.6 Liposomal Delivery Systems
- •5.7 Delivery of Biologicals
- •5.8 RNA-Based Delivery
- •5.9 Therapeutic Proteins and Peptides
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Drugs
- •3. Methods
- •3.1.1 Extrusion-Based 3D Bioprinting
- •3.1.2 Inkjet 3D Bioprinting
- •3.1.3 Light-Based Bioprinting
- •3.1.4 Laser-Assisted Printing
- •3.2 Multiple Drug Delivery
- •3.2.1 Multilayer Films with Capsule-Integrated Polypeptide/Polyelectrolyte
- •3.2.2 Multilayer Shells Using Polypeptides/Polyelectrolytes (PL or PG) and LbL Assembly
- •3.3.1 Physical Stimulation-Responsive Drug Delivery Systems
- •3.3.4 Light-Responsive Drug Delivery Systems (LRDDS)
- •3.4 Small Molecule Delivery System
- •3.4.1 Intraarticular Delivery System
- •3.5 Gene Delivery System
- •3.6 Stem Cell Technology
- •4. Conclusion
- •References
- •1. Introduction
- •2. Importance of Targeted Drug Delivery to the Reproductive System
- •3. Challenges in Drug Delivery to the Reproductive System
- •4. Advances in Drug Delivery Systems
- •4.2 Liposomes
- •4.3 Hydrogels and Biodegradable Polymers
- •4.4 Injectable and Implantable Devices
- •4.5 Micro- and Nano-Needles
- •4.6 Spermbots
- •5.1 Vaginal and Cervical Delivery
- •5.2 Uterine and Intrauterine Delivery
- •5.3 Penile and Testicular Delivery
- •6. Targeted and Precision Medicine Approaches
- •6.1 Hormone Replacement Therapy (HRT)
- •6.2 Gene Therapy and RNA-Based Approaches
- •6.3 Personalized Medicine in Reproductive Disorders
- •7. Therapeutic Applications and Innovations
- •7.1 Infertility and Assisted Reproductive Technologies (ART)
- •7.2 Treatment of Reproductive Cancers
- •7.4 Contraceptive Technologies
- •8. Safety and Regulatory Considerations
- •9. Future Directions and Emerging Trends
- •References
- •1. Introduction
- •2. Liposomes
- •3. Preparation of Liposomes
- •3.1 Reagents
- •3.2 Hydration and Liposome Extrusion
- •3.4 Conjugation
- •3.8 PEGylation
- •3.8.1 Materials Required
- •3.8.2 Procedure
- •3.9 Liposomal Doxorubicin (LD)
- •3.10 Marqibo (Vincristine Sulfate)
- •3.11 DepoCyt (Cytarabine)
- •4. Poly(Lactic-co-Glycolic Acid, PLGA) Nanoparticles
- •4.2 Methods
- •4.2.1 Reagents
- •4.2.2 Procedure
- •5. Polycaprolactone (PCL)
- •5.2 pH Sensitivity and Stability
- •5.3 Methods
- •5.3.1 Materials
- •5.4 Drug Loading
- •6. Chitosan-Based Systems
- •6.1 Encapsulation of Nucleic Acids and Proteins
- •6.3 pH Sensitivity and Stability of Chitosan Nanoparticles
- •6.4 Methodology
- •6.4.1 Reagents
- •6.4.2 Procedure
- •7. Dendrimers
- •7.1 Antisense Oligonucleotides
- •7.2 Small-Interfering RNA (siRNA)
- •7.4.1 Divergent Method
- •7.4.2 Convergent Method
- •8. Challenges in Developing Orphan Drugs
- •References
- •1. Introduction
- •2. Vaccine Delivery Systems
- •3. Polymers
- •4. Non-biodegradable NPs
- •5. Calcium Phosphate NPs
- •6. Colloidally Stable Nanoparticles
- •7. Proteasomes
- •8. Liposomes
- •9. Virus-like Particles (VLPs) and Virosomes
- •10. Immune-Stimulating Complexes ISCOMs
- •11. Emulsion Delivery Systems
- •12. Exosome-Based Vaccine Delivery System
- •13. Immunotherapy Using Nano- and Microparticles
- •14. Properties and Role of Nanoparticles in Drug Delivery
- •15. Biomimicry
- •16. Micellar Systems
- •17. Hydrogels
- •18. Edible Vaccines
- •19. Plant-Derived Viruses
- •20. Melt-in Mouth Strips
- •21. Transdermal Delivery
- •22. Delivery of Nucleic Acids
- •23. mRNA Delivery
- •24. Delivery of Cytokines
- •25. DC Targeting
- •26. Drug Delivery Targeting T Cells
- •27. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Reagents and Solutions
- •3. Methods
- •3.1 Adenovirus
- •3.3 Retroviral Vectors (RV)
- •3.4 Lentivirus (LV)
- •4. Conclusion
- •References
- •1. Introduction
- •2. Technologies Utilizing Cells in Treating Diseases
- •2.1 Somatic Cell Technologies
- •2.2 Immortalized Cell Lines
- •2.5 Genome Editing Technologies
- •2.6 Cell Plasticity Technologies
- •3. Different Kinds of Cells Are Utilized in the Process of Cell Treatment
- •4. The Practices of Regenerative Medicine and Cell Therapy
- •4.1 Veterinary Medicine Therapeutic Uses
- •5. Advancements and Challenges in Drug Delivery
- •6. Drug Delivery Systems and Applications
- •6.2 Drug Nanocarriers Based on Hyaluronic Acid
- •6.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •6.4 Polymer-Lipid Hybrid Nanoparticles
- •6.6 In Situ Gel Drug Delivery System

Chapter 2
Fundamentals of Pharmacokinetics and Drug Delivery
Asha, Puneet Goyal, Pooja, and Ravi Dabas
Abstract
Pharmacokinetics, a subfield of pharmacology, is the study of drug absorption, distribution, metabolism,
and excretion kinetics, including the magnitude and speed of each of these processes. The Greek elements
“pharmakon” (drug) and “kinesis” (movement) are the origin of the English term “pharmacokinetics,”
which describes the movement of a drug. Pharmacokinetics is the mathematical study of the timedependent variation in medication concentrations. So, to sum up, pharmacokinetics is the study of how
medications enter, travel through, and are eliminated from the body by means of metabolism and excretion.
Pharmaceuticals depend on pharmacokinetics research since it determines the dosage, mode of administration, time of peak effect, duration of action, and frequency of drug administration. Principles of pharmacokinetics center on variations in drug concentration brought about by drug absorption, distribution, and
elimination throughout time. There are two primar y ways that drugs and chemicals get beyond biological
membranes: simple transfer and specialized transport. The process by which an unaltered medication enters
the bloodstream from the place of administration is known as absorption. Due to the porosity of the
capillaries, even big lipid-insoluble or ionized medicines are absorbed, whereas lipid-soluble medications
readily pass through the capillary endothelium. The process by which medications enter extravascular fluids
and tissues and leave the bloodstream is known as distribution. This critical pharmacokinetic phase affects
not only the organs involved in metabolism and excretion but also the way that medicines reach their target
areas. The process of changing a substance’s chemical form to one that is more water soluble for simpler
excretion is called metabolism. Particularly, “biotransformation” describes the chemical alterations that
foreign substances go through in the body. There are two main stages of biotransformation. Phase I consists
of processes involving oxidation, reduction, and hydrolysis that add or reveal tiny polar functional groups
(such -OH and -NH2). In order to prepare lipid-soluble medications for Phase II reactions or direct
excretion, this phase alters them to make them more polar. Conjugation is the process by which polar
endogenous compounds (such as sulfate or glucuronic acid) are joined to medications or their Phase I
metabolites in Phase II. This step results in readily excreted conjugates that are soluble in water. The process
of permanently eliminating medications and their metabolites from the body is called excretion. Watersoluble and ionized compounds are excreted more readily by excretory organs—apart from the lungs—than
lipid-soluble ones, which must first be converted into water-soluble forms in order to be excreted more
easily. The drug’s concentration in the body has an impact on pharmacokinetic processes (ADME), and
how that concentration influences the process rate is known as the process order. Key pharmacokinetic
parameters may be computed and the time course of medications in the body can be expressed quantitatively using pharmacokinetic models. Pharmacokinetics is determined by three factors: elimination, distribution and absorption.
Key words Absorption, Distribution, Metabolism, Excretion, Biotransformation
29

30 Asha et al.
1 Introduction
In the branch of science that examines what happens to a material
after it is given to a living thing, pharmacokinetics is the study of
drug distribution, metabolism, excretion, and absorption kinetics,
including the magnitude and rate of each of these processes. It is
necessary to study the rate of drug absorption because, although it
is not always ideal, faster drug absorption results in a faster onset of
medication effect, which is necessary for treating acute disorders
and in emergency situations. Researching the degree of drug
absorption is crucial since the amount of the drug that is absorbed
and enters the systemic circulations is what causes the pharmacological effect [
The pace of medication distribution to its site of affection
impacts the beginning of action and the extent of distribution
defines the degree of the effect. The frequency of drug administration needed during multiple drug administration to make up for
the drug that is removed is determined by the rate of drug elimination. Drugs that are removed more quickly need to be administered
often in order to maintain an effective drug concentration during
the course of many administrations.
The primary pharmacological principle in the therapeutic use of
pharmaceuticals is to pick the appropriate dose regimen for each
individual animal based on the patient’s personal information and
the medication phar macokinetic properties. The patient’s unique
pharmacokinetic parameter can be ascertained during drug administration by using the blood drug concentration measured at a
certain time point.
The combined effects of drug distribution and elimination
processes (metabolism and excretion), which usually happen after
intravenous (IV) injection, are referred to as “drug disposition.”
1].
2 Pharmacokinetic Principles
The main focus of pharmacokinetic principles is how changes in
drug concentration over time are caused by drug absorption, distribution, and elimination. Understanding the relationship
between drug effects and concentration in the body is essential.
Pharmacokinetics is the mathematical study of how drug concentrations change over time. The extent and speed of ADME processes, the right doses and schedules for drugs, the concentrations
of both therapeutic and toxic drugs, the levels of drugs in bodily
fluids and tissues, the half-life and duration of action of drugs, the
impact of diseases on drug kinetics, the duration of drug withdrawal in food animals and the types of drug interactions are all
determined by pharmacokinetic principles [
3] (Fig. 1).

Fundamentals of Pharmacokinetics and Drug Delivery 31
Fig. 1 Flowchart for principles of pharmacokinetics
2.1 Application of the Pharmacokinetic Principle in the Biomedical Fields
• Design and evaluation of dosage forms
• Evaluations of drug formulation
• Pharmacological
• Dosing regimen
3 Cell Membrane/Biological Membrane
The hydrocarbon chains of the amphipathic lipids in the plasma
membrane are orientated inward to produce a continuous hydrophobic phase, while the hydrophilic heads of the lipids are oriented
outward. The bilayer’s individual lipid molecules differ depending
on the specific membrane and have the ability to migrate laterally,
giving the membrane flexibility and fluidity, high relative impermeability to highly polar compounds, and high electrical resistance.
Membrane proteins that are integrated into the bilayer function as
transporters, ion channels, or receptors to trigger chemical or
electrical signaling pathways and offer specific sites for medication
action.
Organs, cells,
categorized and organized by highly specialized molecular barriers
called biological membranes. Medication must pass through one or
more of these membranes in order to reach its intended location,
regardless of the mode of administration. These barriers can be as
simple as a single layer of cells found in enterocytes and renal
tubular epithelial cells, or as complex as many layers of cells found
in the skin, vagina, and placenta. The membranes of individual cells,
mitochondria, and the nucleus are examples of situations where the
barrier can be much thinner. Polar lipid molecules, such as
testing
design
and intracellular activity within the body are

32 Asha et al.
phospholipids, are the main building blocks of biological membranes. These molecules create a bilayer. The hydrophobic (fatty
acid) tails of this bilayer face inward, while the hydrophilic (waterattracting) heads are directed toward the membrane surfaces.
Drug molecules can be carried by bulk water flow, as most cell
membranes are reasonably permeable to water either by diffusion
or flow caused by hydrostatic or osmotic variations across the
membrane. The main method by which medications penetrate the
majority of capillary endothelial membranes is by this type of transport. However, trans-capillary movement is restricted to unbound
drug since bound proteins and drug molecules are too big and
polar for this kind of transport to happen. The amount of paracellular transfer across intercellular gaps is so great that blood flow,
rather than other parameters, is the limiting factor for transit across
most capillaries. This kind of transport plays a crucial role in the
kidney’s glomerular membrane filtration, as will be discussed later.
However, there are significant exceptions to this general rule in
capillary diffusion because certain tissues have “tight” intercellular
connections and have restricted paracellular transit. Tight junctions
are found in the capillaries of the central nervous system (CNS) and
many dif ferent types of epithelial tissues.
3.1 Passage of Drugs Across Biological Membranes
A medication must cross cell membranes in order to be absorbed,
distributed, metabolized, and excreted. Therefore, it is crucial to
understand the mechanisms by which medications cross membranes as well as the physicochemical characteristics of molecules
and membranes that affect this transfer. A drug’s molecular size and
structure, degree of ionization, relative lipid solubility of its ionized
and non-ionized forms, and ability to bind to tissue proteins are its
defining properties.
It goes without saying that a medicine must cross the plasma
membrane of the cell in order to enter the cell. Additional cell layers
(skin) or a single layer of cells (intestinal epithelium) may act as
barriers to the transport of drugs. Since pharmaceuticals generally
travel through cells rather than between them, there are many
common properties that characterize drug dispersion and transport
across these different barriers, despite their structural variations.
Thus, the common barrier is represented by the plasma membrane.
There are two primary ways that drugs and chemicals get beyond
biological membranes: simple transfer and specialized transport
2).
(Fig.
3.1.1 Simple Transport A. Diffusion
One of
the main ways that medications get through biological
membranes is by diffusion, often known as passive diffusion. Under
the influence of the concentration gradient, lipid-soluble compounds and unionized pharmaceuticals pass through the

Fundamentals of Pharmacokinetics and Drug Delivery 33
Fig. 2 Flowchart of methods by which drugs move across the plasma membrane
membrane in this manner without the requirement for energy or
carriers. Until an equilibrium is attained, drugs diffuse from areas of
higher concentration to areas of lower concentration. This process
has no structural character and is not saturable. Water-soluble
medications struggle to permeate lipid membranes, but highly
lipid-soluble pharmaceuticals also diffuse poorly due to their insolubility in bodily fluids. It is easier for drugs with molecular weights
b
etween 100 and 400 Da to diffuse than for bigger molecules.
Diffusion is enhanced by thin membranes and large surface areas,
such as those seen in the lungs and intestine.
When taking into account variables like concentration gradient,
diffusion coefficient, lipid solubility, surface area, and membrane
thickness, Fick’s first law of diffusion provides the best description
of the passive diffusion of drug molecules over a biological
membrane.
Rate of diffusion molecules per unit timeð = C
A × D × K
=
Where, C
is the higher concentration, C2 is the lower concentra-
1
tion, and the difference (C
=w
m
T
- C2) represents the concentration
1
Þ
- C
ð
1
Þ
2
gradient across the membrane. A is the membrane’s surface area,
D is the drug’s diffusion coefficient, K
/w is the lipid-water parti-
m
tion coefficient, and T is the membrane thickness.
The percentage of drug ionized at a particular pH in bodily
fluids and the ratio of ionized to unionized drug are found using
the Henderson-Hassel Balch equation:
For weak acidic drug
pK
- pH = log of concentration of unionized drug
a
=concentration of ionized drug
%ionized drug = 100=1 þ antilog pK
- pHðÞ
a

34 Asha et al.
For weak basic drug
3.1.2 Specialized Transport
pH - pK
= log of concentration of unionized drug
a
=concentration of ionized drug
%ionized drug = 100=1 þ antilog pH - pK
ðÞ
a
B. Filtration
Drugs are filtered when they pass through membrane
or pores
as a result of osmotic pressure variations or hydrostatic
channels
pressure. It mostly affects passive transport-related small molecules
(Mol. wt. <100). It is crucial for the renal excretion (glomerular
filtration) and medication elimination from cerebrospinal fluid,
albeit less significant for the majority of medicines.
A. Active Transport
Solutes require carriers, typically membrane proteins, in the
energy-dependent process of active transport, which allows them
to move against the concentration gradient (from lower to higher
concentration). Because carriers only transfer medications with
particular chemical structures, this mechanism is energy-intensive
and structure-specific. The process can become saturated since
there are only so many carriers, particularly at high drug concentrations where medicines with similar structures may compete for the
same carriers. For large hydrophilic, polar, or electrolyte compounds like methyldopa, L-dopa, and several antimetabolites,
active transport is essential. It is also essential for the excretion of
some medications from the central nervous system and for renal
and biliary excretion.
There are two categories of active transport: primary and secondary. In primary active transport, a carrier moves against the
concentration gradient of a single material by utilizing the energy
from ATP hydrolysis. A driving solute (such as Na, K, or Ca) and a
substrate share a carrier in secondar y active transport. The driving
solute uses the electrochemical gradient produced by cell energy to
propel the substrate’s movement. Co-transport (symport) is the
term used when both move in the same direction; countertransport (antiport) is the term used when they move in opposite
directions. Drugs are less dependent on secondary active transport
than ions and nutrients (Table
1).
B. Facilitated D
A car
rier-mediated transport mechanism called “facilitated dif-
iffusion
fusion” transfers materials downward, following their concentration gradient, without requiring energy. The concentration

Fundamentals of Pharmacokinetics and Drug Delivery 35
Table 1
Difference between simple diffusion and active transport
Serial
No.
Features Simple diffusion Active transport
1. Energy Energy independent (passive
process)
2. Carrier Not required Required
3. Movement of drug Along the concentration
gradient
4. Saturation Non-saturable process Saturable process
5. Competitive
inhibition
6. Structure specificity Not required Required
7. Nature and type of
drug
8. Occurrence Wide occurrence in body Limited to certain parts
Do not occur May occur
Lipid soluble and unionized Mainly hydrophilic, polar and
Energy dependent (active process)
Against the concentration gradient
electrolyte
gradient drives the passive process of membrane crossing even
though a carrier helps. It can move materials that cannot disperse
on their own and is quicker than ordinary diffusion. It is structurespecific, saturable, and competitive with other agents of a similar
nature to active transport. Nevertheless, unlike the symports and
antiports of active transport, assisted diffusion uses uniports, which
only move a single molecule at a time. Examples include the uptake
of
specific vitamins and the entrance of glucose into red blood cells.
One of the less important drug transport mechanisms is facilitated
diffusion.
C. Pinocytosis
A small transpor
t process called pinocytosis forms extracellular
drug droplets into vesicles by engulfing them in a section of the cell
membrane. The vesicles are subsequently internalized and transferred between cell membranes. Phagocytosis and this process are
comparable; however, liquid droplets are used in place of solid
particles. Sometimes, endocytosis is used to refer to both processes.
In addition to having competitive saturation kinetics and some
structural selectivity, pinocytosis consumes cellular energy. It is in
charge of taking in big proteins, some medications, such as insulin,
and macromolecular nutrients. It also absorbs vaccines, like the
Sabin Polio vaccine.

36 Asha et al.
4 Routes of Drug Administration
There are several ways to administer drugs, and each has pros and
cons of its own [
15].
4.1 Oral (Enteral) Versus Parenteral Administration
4.2 Various Routes of Drug Administration
• Oral administration is the most popular and practical approach.
Although it has benefits like cost-effectiveness and safety, food,
digestive enzymes, and medication solubility may impede its
absorption. Although controlled-release formulations may
result in patient variability, they can enhance drug absorption.
When oral delivery is not possible, there are several routes that
allow faster absorption or avoid the liver’s first-pass effect: sublingual and rectal.
• When oral administration is not an option or is an emergency,
peripheral administration (injection) provides quick, accurate
drug delivery. Risks associated with intravenous injections
include possible responses and the dose’s irreversibility, but
they also provide regulated, immediate effects and avoid problems with absorption. Subcutaneous and intramuscular injections are two other parenteral techniques that provide slower,
persistent absorption. Moreover, specific organs or tissues can be
targeted with intrathecal, topical, intraarterial, and pulmonary
applications. Depending on the substance and circumstance,
each approach has advantages and disadvantages.
1. Oral (enteral) administration is the most common, convenient, and economical method, being noninvasive and easy
for self-administration. However, absorption can be inconsistent due to factors like food, enzymes, or pH and first-pass
metabolism in the liver can reduce drug efficacy. It’s also
unsuitable for patients who are vomiting or unconscious.
2. Sublingual administration provides rapid absorption directly
the bloodstream, bypassing
into
first-pass metabolism, but it
is limited to small doses and certain drugs.
3. Rectal administration is useful for patients who can’t take drugs
orally and partially bypasses first-pass metabolism, though
absorption can be irregular and may irritate the rectal mucosa.
4. Intravenous (IV) administration
ensures immediate
and complete bioavailability, allowing controlled and accurate drug
delivery, but it requires aseptic conditions and skilled administration, with risks of infection, rapid adverse reactions, and
irreversibility once the drug is administered.
5. Intramuscular (IM) injections of
fer rapid absorption for aqueous solutions and sustained release for depot formulations,
though they may cause pain, tissue damage, and slower absorption in obese individuals, with a risk of accidental injection into
blood vessels.

Fundamentals of Pharmacokinetics and Drug Delivery 37
6. Subcutaneous (SC) injections provide slower, sustained drug
release and are less invasive than IV or IM routes, but they are
limited to non-irritating drugs and can be painful, with a
restricted volume of administration.
7. Inhalation offers rapid absorption due to the large lung surface
area and is ideal for local delivery to the lungs, such as in asthma
treatment, but it requires proper technique and dose control
can be challenging.
8. Topical administration provides localized effects, minimizing
systemic side effects, with
transdermal
patches offering controlled, sustained release, though absorption is slow through
intact skin and limited to lipid-soluble drugs.
9. Intrathecal administration delivers drugs directly into the cerebrospinal
fluid (CSF), bypassing
the blood–brain barrier, which
is useful for spinal anesthesia or CNS infections, but it requires
expert administration and carries a high risk of complications.
10. Intraar terial administration targets specific organs or tissues,
as in
such
treating liver tumors, but it is technically challenging
and risky, with potential for local tissue damage.
Each route has specific benefits based on the drug and the
patient’s condition, but they also come with inherent limitations and risks.
5 Absorption
5.1 Factors Affecting Absorption of Drugs
5.1.1 Physio-chemical Characteristics
The process by which an unaltered medication enters the bloodstream from the place of administration is known as absorption.
Drug absorption is necessary for all systemic routes, with the
exception of intravascular ones, in order for the medication to
reach its target in the circulation and start working. The effectiveness of a medicine is dependent on its pace and degree of absorption; a drug that absorbs slowly may not reach its minimal effective
concentration, whereas a substance that absorbs quickly may attain
therapeutic levels quite soon. Drugs must dissolve in bodily fluids
in solid forms, such as powders, capsules, and tablets, in order for
them to be absorbed, regardless of the mode of administration [
2].
Several factors affect the rate and degree of medication absorption.
Absorption is influenced by molecule size, pK, and lipid solubility.
Drugs that are unionized and lipid-soluble are absorbed more
quickly.

38 Asha et al.
5.1.2 Dosage Form
Compared to oily, suspension, or solid forms, drugs in aqueous
solutions are absorbed more quickly. Absorption is also influenced
by the rate of dissolution; liquids often absorb more quickly than
pills or sustained-release goods.
5.1.3 Concentration and Volume
5.1.4 Blood Flow By preserving the concentration gradient, improved blood flow to
A steeper concentration gradient causes higher drug concentrations
and quantities to be absorbed more quickly.
the absorption site improves medication absorption.
5.1.5 Surface Area Faster absorption is achieved by larger absorbent surfaces, such as
the intestine as opposed to the stomach.
5.1.6 Administration Route
Different routes have different rates of absorption; pulmonary and
intramuscular (IM) routes absorb drugs more quickly than subcutaneous (SC) or oral methods.
5.1.7 Disease States By changing pH, membrane permeability, or blood flow, illnesses
such acid-base imbalances, infections, and cardiovascular disorders
can have an impact on absorption.
5.2 Gastrointestinal Tract
For systemic medications, the oral route is frequently used. Drugs
enter the stomach through the esophagus and mouth after consumption. Although absorption is supported by the abundant
blood supply and thin epithelium of the oral mucosa, significant
absorption is limited by the mouth’s brief period of contact.
Because of its quick passage time, the esophagus does not absorb
medicines either. The gastrointestinal (GI) tract’s epithelial lining
serves as the primary barrier. According to the pH-partition
hypothesis, acidic medications are better absorbed in the stomach
and basic pharmaceuticals in the intestine. Lipid-soluble and
unionized drugs are absorbed by diffusion. The majority of medications are instead absorbed in the intestine, which has a big surface
area and ideal circumstances, whereas stomach absorption is
restricted by the thick gastric mucosa and small surface area [
Food can
slow down and dilute absorption in the GI tract.
5].
While digestive juices aid in the dissolution of medications, they
can also render certain inactive (such as insulin and penicillin-G).
Reduction of absorption can also occur from drug metabolism by
gut bacteria or enzymes. While high intestinal motility can reduce
absorption, rapid gastric emptying often improves it. Drugs taken
concurrently may have an impact on absorption and varying reactions may result from variables such as drug size, dosage for m, GI
tract variations, and pathological states.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
